Search results
We must remember the heroes of the AIDS epidemic, not just the trauma
LA Times via Yahoo News· 6 days agoAIDS activist Cleve Jones rides at the front of the Utah Pride parade in downtown Salt... /...
The Evolution of Vaccinology: From Humble Beginnings to Advanced Science | JD Supra
JD Supra· 6 days agoFor centuries, humans have sought ways to protect from deadly diseases. The practice of intentionally exposing healthy people to smallpox, a practice...
7 Stocks That Could Safely 10X by 2030
InvestorPlace· 6 days agoHere are seven possible 10x stocks worth looking into. Cloudflare (NYSE:NET) provides vital internet security and performance services to a huge portion...
HIV/AIDS Fast Facts
KEYT 3 Santa Barbara· 6 days agoCNN Editorial Research (CNN) — Here’s a look at the origins, treatments and global response to HIV and AIDS.FactsHIV stands for human
Business of Pride: Dr. Eliav Barr of Merck ensures LGBTQ inclusion in clinical trials — and in the...
The Business Journals· 22 hours agoThis story is part of the Philadelphia Business Journal's 2024 Business of Pride series, profiling local individuals and companies undertaking initiatives in support of the region's LGBTQ+ community ...
Hunter Biden's ex-wife and former girlfriend testify at trial about finding his drug paraphernalia
The Globe Gazette· 6 days agoHunter Biden's ex-wife and a former girlfriend testified Wednesday in his gun trial about finding...
Lilly announces departure of Anat Ashkenazi, chief financial officer - Eli Lilly and Co (NYSE:LLY)
Benzinga· 7 days agoEli Lilly and Company LLY announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our ...
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in...
Morningstar· 6 days ago(NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast ...